Michigan experience using the Tigertriever device to remove brain clots
Official title: Michigan Initial Experience Using Tigertriever for Thrombectomy
Run by Henry Ford Health System · NCT07363525 · Data updated 2026-11-12
This project tries to see if the Tigertriever device safely and effectively removes large brain clots in adults who have an ischemic stroke within 8 hours of symptom onset.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Henry Ford Health System Academic / other |
| Locations | 1 site (Detroit, Michigan) |
| Status | Recruiting |
| Started | January 15, 2026 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | May 8, 2026 |
| Trial ID | NCT07363525 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) admitted with a large vessel occlusion ischemic stroke who are treated with the Tigertriever as the first-line thrombectomy device and can provide informed consent are ideal candidates.
✕Probably not a fit
Patients with acute intracranial hemorrhage on admission imaging, recent stroke/hemorrhage/thrombolysis or endovascular therapy within 3 months, significant pre-stroke disability (mRS ≥2), or those not treated with Tigertriever are unlikely to benefit from inclusion.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational, real-world collection of outcomes from patients with large vessel occlusion who are treated with the Tigertriever device as first-line mechanical thrombectomy at Henry Ford Hospital. Treatment follows standard of care and no experimental procedures are added; researchers will collect procedural and safety data and a clinical follow-up visit at 3 months. Key data include restoration of blood flow after clot removal, procedure-related complications such as hemorrhage, and functional status at follow-up. Eligible patients are adults with LVO treated with Tigertriever, excluding those with acute hemorrhage on imaging, recent stroke/hemorrhage/thrombolysis/endovascular therapy within 3 months, or significant pre-stroke disability.
Why it matters
Potential benefit: If successful, the data could support that the Tigertriever is a safe and effective option for removing large clots and improving recovery after ischemic stroke.
How similar studies have gone: Mechanical thrombectomy with stent-retriever devices has been proven effective in large trials, and smaller reports of newer devices like Tigertriever have shown promising but more limited experience.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as per the approved indication. 2. Tigertriever was used as the first line treatment in the target vessel. 3. A signed informed consent. 4. Age ≥ 18. Exclusion Criteria: -1. Evidence of acute brain hemorrhage on NCCT or MR at admission. 2. Prior hemorrhage, stroke, thrombolysis, and/or endovascular therapy in the last 3 months. 3\. pre-stroke disability (pre-stroke mRS ≥ 2).
Where it's running
-
Henry Ford Hospital
Detroit, Michigan, United States Recruiting
Study contacts
- Study coordinator: Alex Chebl, MD
- Email: achebl1@hfhs.org
- Phone: 313-916-2644
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Anesthesia choice for mechanical thrombectomy in ischemic stroke
In people with severe ischemic stroke due to a large vessel blockage who need mechanical thrombectomy, this study tests whether general anesthesia works better than procedural sedation for improving daily function 3 months later.
-
Assessing immune responses after acute ischemic stroke treatment
This study is testing how the immune system reacts in patients treated for an acute ischemic stroke to see if these responses can help predict their recovery after three months.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Remote ischemic conditioning for post-stroke insomnia
A 136-person, randomized study will test whether a non-invasive arm-cuff procedure done twice daily for 90 days can improve sleep after a first ischemic stroke in adults 18–80.
-
Ear-based nerve stimulation to help sleep after a stroke
A device that delivers vagal nerve stimulation through the ear is tested to see if it helps stroke patients in rehab sleep better.
-
Theta Burst Stimulation to Help Stroke Recovery (Upper and Lower Limbs)
This trial tests whether applying theta burst stimulation to the motor cortex, in combination with standard rehabilitation, helps people over 45 who recently had a first ischemic stroke recover arm and leg movement.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.